Clinical Laboratory, Hunan University of Medicine General Hospital, Huaihua, Hunan, 418000, China.
Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100010, China.
Genes Genomics. 2024 Apr;46(4):437-449. doi: 10.1007/s13258-024-01505-x. Epub 2024 Mar 4.
Bladder cancer is a prevalent malignancy. CDC20, a pivotal cell cycle regulator gene, plays a significant role in tumour cell proliferation, but its role in bladder cancer remains unclear.
This study aimed to analyse CDC20 expression in bladder cancer and explore its roles in tumour progression, treatment response, patient prognosis, and cellular proliferation mechanisms.
We systematically analysed CDC20 expression in bladder cancer using bioinformatics. Our study investigated the impact of CDC20 on chemotherapy and radiotherapy sensitivity, patient prognosis, and changes in CDC20 methylation levels. We also explored the role and potential underlying mechanisms of CDC20 in bladder cancer cell growth. We used lentiviral transfection to downregulate CDC20 expression in 5637 and T24 cells, followed by CCK-8, colony formation, scratch, invasion, apoptosis, and cell cycle analyses.
CDC20 is highly expressed in bladder cancer and is significantly correlated with poor prognosis. Moreover, CDC20 demonstrated high diagnostic potential for bladder cancer (AUC > 0.9). The tumour methylation levels of CDC20 in tumour tissues markedly decreased compared with those in normal tissues, and lower methylation levels were associated with a worse prognosis. Elevated CDC20 expression is linked to increased mutation burden. Our findings suggested a potential association between high CDC20 expression and resistance to chemotherapy and radiotherapy, as CDC20 expression may impact immune cell infiltration levels. Mechanistic analysis revealed the influence of CDC20 on bladder cancer cell proliferation through cell cycle-related pathways. According to the cell experiments, CDC20 downregulation significantly impedes bladder cancer cell proliferation and invasion, leading to G1 phase arrest.
Aberrantly high CDC20 expression promotes tumour progression in bladder cancer, resulting in a poor prognosis, and may also constitute a promising therapeutic target.
膀胱癌是一种常见的恶性肿瘤。CDC20 是一个关键的细胞周期调节基因，在肿瘤细胞增殖中发挥重要作用，但它在膀胱癌中的作用尚不清楚。
本研究旨在分析膀胱癌中 CDC20 的表达，并探讨其在肿瘤进展、治疗反应、患者预后和细胞增殖机制中的作用。
我们系统地使用生物信息学分析了 CDC20 在膀胱癌中的表达。我们的研究调查了 CDC20 对化疗和放疗敏感性、患者预后和 CDC20 甲基化水平变化的影响。我们还探讨了 CDC20 在膀胱癌细胞生长中的作用和潜在机制。我们使用慢病毒转染下调 5637 和 T24 细胞中的 CDC20 表达，然后进行 CCK-8、集落形成、划痕、侵袭、凋亡和细胞周期分析。
CDC20 在膀胱癌中高表达，与预后不良显著相关。此外，CDC20 对膀胱癌具有较高的诊断潜力（AUC>0.9）。肿瘤组织中 CDC20 的肿瘤甲基化水平明显低于正常组织，较低的甲基化水平与预后不良相关。CDC20 表达水平升高与突变负担增加有关。我们的研究结果表明，CDC20 高表达与化疗和放疗耐药之间可能存在关联，因为 CDC20 表达可能影响免疫细胞浸润水平。机制分析表明，CDC20 通过细胞周期相关途径影响膀胱癌细胞的增殖。根据细胞实验，下调 CDC20 显著抑制膀胱癌细胞的增殖和侵袭，导致 G1 期停滞。
CDC20 表达异常升高促进膀胱癌肿瘤进展，导致预后不良，也可能成为有前途的治疗靶点。
